Cartesian Therapeutics Inc
RNAC7.550USD
-0.120-1.56%
收盘 11/06, 16:00（美东）报价延迟15分钟
196.30M总市值
亏损市盈率 TTM
关于 Cartesian Therapeutics Inc 公司
Cartesian Therapeutics, Inc. 是一家临床阶段公司。该公司致力于开发用于治疗自身免疫性疾病的信使核糖核酸 (mRNA) 细胞疗法。该公司正在利用其专有技术和制造平台 RNA Armory 开发用于治疗自身免疫性疾病的 mRNA 细胞疗法。其主要资产 e，Descartes-08，是一种针对 B 细胞成熟抗原 (BCMA) 的自体 mRNA 嵌合抗原受体 T 细胞疗法 (CAR-T)，该公司正在开发用于治疗自身免疫性疾病。Descartes-08 正处于 II 期临床开发阶段。Descartes-15 是下一代自体抗 BCMA mRNA CAR-T。利用其专有技术和制造平台，该公司设计了 Descartes-15，使其在多次抗原暴露后比 Descartes-08 更能抵抗 CAR 的回收。该公司正在开发 Descartes-33，以提供针对自身免疫发病机制中关键驱动因素的治疗性蛋白质组合。
Cartesian Therapeutics Inc简介
公司代码RNAC
公司名称Cartesian Therapeutics Inc
上市日期Jun 22, 2016
CEODr. Carsten Brunn, Ph.D.
员工数量66
证券类型Ordinary Share
年结日Jun 22
公司地址7495 New Horizon Way
城市FREDERICK
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编21703
电话13013488698
网址https://www.cartesiantherapeutics.com/
公司代码RNAC
上市日期Jun 22, 2016
CEODr. Carsten Brunn, Ph.D.
Cartesian Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
3.82K
-14.03%
Dr. Kemal Malik
Dr. Kemal Malik
Independent Director
Independent Director
--
-100.00%
Dr. Michael S. Singer, M.D., Ph.D.
Dr. Michael S. Singer, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Timothy C. (Tim) Barabe
Mr. Timothy C. (Tim) Barabe
Independent Director
Independent Director
--
--
Dr. Nishan M. de Silva, M.D.
Dr. Nishan M. de Silva, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Murat Kalayoglu, M.D., Ph.D.
Dr. Murat Kalayoglu, M.D., Ph.D.
Independent Director
Independent Director
502.42K
-1.74%
Dr. Emily English, Ph.D.
Dr. Emily English, Ph.D.
Chief Operations Officer
Chief Operations Officer
36.95K
+25.46%
Dr. Carsten Brunn, Ph.D.
Dr. Carsten Brunn, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
30.24K
-38.23%
Dr. Milos Miljkovic, M.D.
Dr. Milos Miljkovic, M.D.
Chief Medical Officer
Chief Medical Officer
17.12K
--
Mr. Blaine Davis
Mr. Blaine Davis
Chief Financial Officer
Chief Financial Officer
12.21K
-87.12%
Mr. Patrick J. (Pat) Zenner
Mr. Patrick J. (Pat) Zenner
Lead Independent Director
Lead Independent Director
3.82K
-14.03%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月14日 周四
更新时间: 8月14日 周四
持股股东
股东类型
持股股东
持股股东
占比
Springer Timothy A
33.22%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.98%
Singer (Michael S.)
2.72%
MPM BioImpact LLC
2.64%
其他
34.93%
持股股东
持股股东
占比
Springer Timothy A
33.22%
Seven One Eight Three Four Irrevocable Trust
17.52%
Fidelity Management & Research Company LLC
8.98%
Singer (Michael S.)
2.72%
MPM BioImpact LLC
2.64%
其他
34.93%
股东类型
持股股东
占比
Individual Investor
39.87%
Corporation
20.04%
Investment Advisor
17.88%
Investment Advisor/Hedge Fund
5.51%
Hedge Fund
1.66%
Research Firm
0.24%
Insurance Company
0.08%
Bank and Trust
0.05%
Pension Fund
0.03%
其他
14.64%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
181
6.62M
25.45%
-1.00M
2025Q2
206
22.27M
85.81%
-1.28M
2025Q1
226
22.94M
90.08%
+138.68K
2024Q4
230
22.26M
88.90%
-105.22K
2024Q3
229
20.22M
92.77%
+6.58M
2024Q2
235
14.41M
85.20%
+9.02M
2024Q1
233
3.74M
346.71%
-1.42M
2023Q4
240
3.82M
71.00%
-922.87K
2023Q3
251
3.63M
70.60%
-1.17M
2023Q2
261
3.72M
72.70%
-649.68K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Springer Timothy A
8.64M
33.22%
+22.36K
+0.26%
Apr 14, 2025
Seven One Eight Three Four Irrevocable Trust
4.56M
17.52%
--
--
Apr 14, 2025
Fidelity Management & Research Company LLC
2.33M
8.98%
-5.79K
-0.25%
Jun 30, 2025
Singer (Michael S.)
707.06K
2.72%
-623.00
-0.09%
Apr 14, 2025
MPM BioImpact LLC
686.01K
2.64%
-104.77K
-13.25%
Jun 30, 2025
TAS Partners, L.L.C.
656.51K
2.52%
+126.72K
+23.92%
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
582.03K
2.24%
-26.00K
-4.28%
Jun 30, 2025
Invus Public Equities Advisors, LLC
563.27K
2.17%
--
--
Jun 30, 2025
Kalayoglu (Murat)
502.42K
1.93%
-8.88K
-1.74%
Apr 14, 2025
The Vanguard Group, Inc.
496.37K
1.91%
-7.17K
-1.42%
Jun 30, 2025
查看更多
持股ETF
更新时间: 23 小时前
更新时间: 23 小时前
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Biotechnology ETF
0.01%
ALPS Medical Breakthroughs ETF
0%
Global X Russell 2000 ETF
0%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.72%
Invesco Nasdaq Biotechnology ETF
占比0.03%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
iShares Micro-Cap ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%
ALPS Medical Breakthroughs ETF
占比0%
Global X Russell 2000 ETF
占比0%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0%
Proshares Ultra Russell 2000
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
公告日期
类型
比率
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
Mar 28, 2024
Merger
30→1
